ATM
Asset Logo

Aneka Tambang (Persero) Tbk (Pt)

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💰 Dividends

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💰

1.19%
Annual dividend yield

Based on the most recent dividend

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

PT Aneka Tambang Tbk engages in the exploration, exploitation, processing, refining, and marketing of minerals, precious metals, and coal. The company is headquartered in Jakarta Selatan, Dki Jakarta and currently employs 4,013 full-time employees. The firm is engaged in the exploration, exploitation, processing, refining and marketing of nickel ore, ferronickel, gold, silver, bauxite, coal and other precious metals. The company operates in three segments, which comprised of nickel, gold and refinery, and bauxite and alumina. Its gold & precious metal refining business segment consists of gold commodity, silver and precious metals processing and refinery services. The gold ore mining is produced from two mining sites: Pongkor, West Java and Cibaliung, Banten. Bauxite contains alumina (AI203) and a mixture of silica, various iron oxides, and titanium dioxide. The company is produced in Tayan Bauxite Mining, West Kalimantan. Its nickel operating segment is comprised of ferronickel and nickel ore sales. Its ferronickel production is operated from the Company’s Southeast Sulawesi Nickel Mining Business Unit.

📈 Performance

Price History

-8.00%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💰 Dividends

Payouts

💰 Annual Dividend Yield*

1.19%

💰 Annual Dividend Earnings Per $1,000 invested**

$11.86

💰 Most Recent Dividend Franked Percentage Estimate

0.00%

💰 Average Dividend Franked Percentage Estimate

0.00 %

💰 Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$0.00

0.00%

2022

$0.00

0.00%

2021

$0.01

NaN%

2020

$0.00

NaN%

2019

$0.01

NaN%

2018

$0.00

0.00%

2017

$0.00

0.00%

2016

$0.00

0.00%

2015

$0.00

0.00%

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$1.15

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ATM

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in ATM

N/A
ATM investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in ATM also invest in...

Want more shares? Try these...

ATOM

ATOM.AX was created on 2022-12-07 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Uranium & Nuclear Components Total Return Index

📊 Share price

$10.25 AUD
Find Out More

Atlas Pearls Ltd. produces white & silver South Sea pearls and farming operations in Indonesia. The company is headquartered in Perth, Western Australia. The firm is a producer of South Sea pearls, specializing in white and silver pearls. The firm operates approximately seven pearl farms throughout the Indonesian archipelago, from the national park lands of Banyu Biru to Flores, and as far east as West Papua. The firm is a fully integrated business including hatchery, seeding, harvesting, grading, trading, design and manufacturing capabilities to sell directly to customers through wholesale partners and via its retail outlets. The firm provides a range of products, such as DOUBLE PEARL BRACELET, CAGE PENDANT , KESHI STUDS, VINE RING, SIMPLE SHEPHERD HOOK EARRINGS, TOP HAT PENDANT, SICKLE PEARL RING, NEOPRENE PEARL BRACELET, FLAT BUTTON STUDS, BUBBLED RING , NEOPRENE PEARL BRACELET, FIXED PENDANT, FILAGREE CUP STUD, FLOWER FILAGREE PENDANT, PAVED DIAMOND PENDANT, OPEN PETAL RING, SIMPLE SHEPHERD HOOK EARRINGS and CAGE PENDANT.

📊 Share price

$0.04 AUD

ATEC

ATEC.AX was created on 2020-03-04 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 175.82m in AUM and 38 holdings. The investment objective of the Fund is to provide an investment return that aims to track the performance of the S&P/ASX All Technology Index (the Index), before taking into account fees and expenses.

📊 Share price

$18.71 AUD

Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company is headquartered in Melbourne, Victoria and currently employs 12 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

📊 Share price

$0.01 AUD
Compare
Add to watchlist